Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 8/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9536389 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPK1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL10338831 | 0.77 | ALDH1A1 (0.65) | ALDH1A1MAPK1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL25529239 | 0.75 | MAPK1 (0.43) | ALDH1A1MAPK1POLBSMN1; SMN2TSHR | |
| SCHEMBL25529231 | 0.74 | ALDH1A1 (0.40) | ALDH1A1POLBSMN1; SMN2MAPTTSHR | |
| SCHEMBL17297923 | 0.73 | MYC (0.38) | KCNK3ALOX15 | |
| SCHEMBL17297805 | 0.70 | CNR2 (0.35) | KCNK3KDM4E | |
| SCHEMBL27218042 | 0.69 | MAPK1 (0.41) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL27218084 | 0.69 | MAPK1 (0.40) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL31180529 | 0.68 | NR1H2 (0.47) | ALDH1A1MAPK1SMN1; SMN2MAPTTSHR | |
| SCHEMBL25529232 | 0.67 | SMN1; SMN2 (0.44) | ALDH1A1POLBSMN1; SMN2MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117440951-A | Pyridone compounds and methods of use | 埃克塞里艾克西斯公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-4110779-A1 | COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022178205-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | ALDH1A1 3998/4885MAPK1 310/4885POLB 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.